Nuvectis Pharma (NVCT) Competitors $6.43 +0.06 (+0.94%) Closing price 04:00 PM EasternExtended Trading$6.42 -0.01 (-0.16%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. DNTH, VIR, ANAB, TSHA, ORGO, TBPH, MAZE, MRVI, KROS, and BCAXShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Dianthus Therapeutics (DNTH), Vir Biotechnology (VIR), AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Theravance Biopharma (TBPH), Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Dianthus Therapeutics Vir Biotechnology AnaptysBio Taysha Gene Therapies Organogenesis Theravance Biopharma Maze Therapeutics Maravai LifeSciences Keros Therapeutics Bicara Therapeutics Nuvectis Pharma (NASDAQ:NVCT) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Which has more risk and volatility, NVCT or DNTH? Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Is NVCT or DNTH more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -150.81% -94.84% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Which has stronger earnings and valuation, NVCT or DNTH? Nuvectis Pharma has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$19M-$1.17-5.50Dianthus Therapeutics$6.24M104.46-$84.97M-$3.25-6.23 Do analysts prefer NVCT or DNTH? Nuvectis Pharma currently has a consensus target price of $15.33, suggesting a potential upside of 138.47%. Dianthus Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 161.73%. Given Dianthus Therapeutics' higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer NVCT or DNTH? In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 12 articles in the media. Nuvectis Pharma's average media sentiment score of 0.58 beat Dianthus Therapeutics' score of 0.07 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of NVCT or DNTH? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryNuvectis Pharma beats Dianthus Therapeutics on 7 of the 13 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.16M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-5.5020.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book9.748.608.826.15Net Income-$19M-$54.65M$3.25B$265.06M7 Day Performance4.21%5.43%4.05%2.80%1 Month Performance-21.78%6.75%4.32%1.68%1 Year Performance1.10%31.59%36.25%29.59% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma3.6267 of 5 stars$6.43+0.9%$15.33+138.5%-1.4%$162.16MN/A-5.508News CoverageShort Interest ↓Analyst RevisionDNTHDianthus Therapeutics1.1871 of 5 stars$18.89+0.7%$53.00+180.6%-21.2%$603.32M$6.24M-5.8180News CoverageEarnings ReportAnalyst RevisionVIRVir Biotechnology3.2062 of 5 stars$4.28-0.5%$30.25+606.8%-46.2%$597.34M$74.21M-1.07580Analyst RevisionGap DownANABAnaptysBio3.1185 of 5 stars$20.00-4.9%$47.75+138.8%-37.8%$588.78M$91.28M-4.46100Analyst ForecastAnalyst RevisionGap DownTSHATaysha Gene Therapies3.4977 of 5 stars$2.76+1.5%$8.17+195.9%+32.9%$583.88M$8.33M-8.12180News CoverageEarnings ReportAnalyst ForecastORGOOrganogenesis4.2165 of 5 stars$4.61+1.3%$7.50+62.7%+84.6%$577.84M$482.04M-32.93950Earnings ReportTBPHTheravance Biopharma2.106 of 5 stars$11.40-1.0%$21.33+87.1%+50.0%$576.02M$64.38M-9.66110News CoverageMAZEMaze TherapeuticsN/A$13.47+2.5%$25.60+90.1%N/A$575.49M$167.50M0.00121News CoveragePositive NewsEarnings ReportMRVIMaravai LifeSciences3.7033 of 5 stars$2.06-6.4%$6.64+222.3%-67.4%$560.25M$259.18M-1.81610News CoverageAnalyst ForecastGap DownKROSKeros Therapeutics2.4511 of 5 stars$13.35-2.8%$30.00+124.7%-68.7%$557.65M$3.55M43.07100Analyst RevisionBCAXBicara Therapeutics1.9914 of 5 stars$9.99-2.1%$31.86+218.9%N/A$556.27MN/A0.0032News CoveragePositive NewsEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies DNTH Alternatives VIR Alternatives ANAB Alternatives TSHA Alternatives ORGO Alternatives TBPH Alternatives MAZE Alternatives MRVI Alternatives KROS Alternatives BCAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access